May 10, 2022 09:31 AM EDT
R&D
FDA+

Bio­gen piv­ots to sec­ond amy­loid-tar­get­ed Alzheimer's drug with ac­cel­er­at­ed ap­proval fil­ing from part­ner Ei­sai

Zachary Brennan

Senior Editor

Al­most ex­act­ly a year ago, Bio­gen CEO Michel Vounatsos boast­ed that the com­pa­ny’s new Alzheimer’s drug, prep­ping for bil­lions in sales fol­low­ing its quick FDA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times